Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q2 EPS of ($0.47), versus ($0.62) reported last year. Revenue for the quarter came in at $36.75 million, versus $46.98 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• CalPrivate Bank names Andra Frazier as chief credit officer
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown